Gilead Sciences, Inc. vs PulteGroup, Inc. — how do they compare? Gilead Sciences, Inc. trades at $147 (market cap $182.09B), while PulteGroup, Inc. trades at $113.37 (market cap $21.63B). The key difference: Gilead Sciences, Inc. is far larger — about 8.4× PulteGroup, Inc.'s market cap, and Gilead Sciences, Inc. pays the higher dividend (2.23%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and PulteGroup, Inc. for 91 Days on average.
| GILD | PHM | |
|---|---|---|
Market Cap | $182.09B | $21.63B |
Volume | 4,960,247 | 2,324,729 |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $142.56 |
52-Week Low | $116.74 | $110.11 |
Typical Hold Time | 111 Days | 91 Days |
Enterprise Value | $205.15B | $22.04B |
Dividend Yield | 2.23% | 0.92% |
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% with bullish technical signals and strong analyst support. Recent earnings beat expectations in three consecutive quarters, though Q2 showed a significant loss. The company maintains robust operating cash flow of $10.02B (2025) and expanded HIV prevention access through a major PAHO partnership. Valuation metrics show a P/E of 17.84 and P/S of 6.02, with revenue growth from $29.44B (2025) to projected $30.5B (2026).
Outlook remains positive with 65% analyst buy ratings and $151.57 consensus target, though risks include negative net income margin (-10.64%) and high debt levels. The stock offers dividend income ($0.82 upcoming) and pipeline catalysts in oncology/HIV, but investors should monitor earnings volatility and competitive pressures in biopharma.
PulteGroup (PHM) trades at $112.33, down 3.25% amid broader housing sector pressure from rising mortgage rates. The stock shows bearish technical signals with recent earnings misses but maintains solid fundamentals including an 11.47 P/E ratio and 14.9% ROE. Cash flow remains positive at $355 million for 2025, though revenue and margins have softened from 2024 peaks. The company continues dividend payments with a $0.26 quarterly payout scheduled for October 2026.
PHM presents a mixed outlook with attractive valuation metrics offset by near-term headwinds. The consensus price target of $139.80 suggests 24% upside potential, but rising interest rates pose significant risk to housing demand. Investors face tension between Wall Street's bullish price targets and current technical weakness, requiring careful monitoring of Q3 2026 earnings due October 22nd for directional clarity.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →